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Abstract
Introduction Similar to matrix metalloproteinases, glycosidases
also play a major role in cartilage degradation. Carbohydrate
cleavage products, generated by these latter enzymes, are
released from degrading cartilage during arthritis. Some of the
cleavage products (such as hyaluronate oligosaccharides) have
been shown to bind to Toll-like receptors and provide
endogenous danger signals, while others (like N-acetyl
glucosamine) are reported to have chondroprotective functions.
In the current study for the first time we systematically
investigated the expression of glycosidases within the joints.
Methods Expressions of β-D-hexosaminidase,  β-D-
glucuronidase, hyaluronidase, sperm adhesion molecule 1 and
klotho genes were measured in synovial fibroblasts and synovial
membrane samples of patients with rheumatoid arthritis and
osteoarthritis by real-time PCR. β-D-Glucuronidase,  β-D-
glucosaminidase and β-D-galactosaminidase activities were
characterized using chromogenic or fluorogenic substrates.
Synovial fibroblast-derived microvesicles were also tested for
glycosidase activity.
Results According to our data, β-D-hexosaminidase,  β-D-
glucuronidase, hyaluronidase, and klotho are expressed in the
synovial membrane. Hexosaminidase is the major glycosidase
expressed within the joints, and it is primarily produced by
synovial fibroblasts. HexA subunit gene, one of the two genes
encoding for the alpha or the beta chains of hexosaminidase,
was characterized by the strongest gene expression. It was
followed by the expression of HexB subunit gene and the β-D-
glucuronidase gene, while the expression of hyaluronidase-1
gene and the klotho gene was rather low in both synovial
fibroblasts and synovial membrane samples. Tumor growth
factor-β1 profoundly downregulated glycosidase expression in
both rheumatoid arthritis and osteoarthritis derived synovial
fibroblasts. In addition, expression of cartilage-degrading
glycosidases was moderately downregulated by
proinflammatory cytokines including TNFα, IL-1β and IL-17.
Conclusions According to our present data, glycosidases
expressed by synovial membranes and synovial fibroblasts are
under negative regulation by some locally expressed cytokines
both in rheumatoid arthritis and osteoarthritis. This does not
exclude the possibility that these enzymes may contribute
significantly to cartilage degradation in both joint diseases if
acting in collaboration with the differentially upregulated
proteases to deplete cartilage in glycosaminoglycans.
DMEM: Dulbecco's modified Eagle's medium; FCS: fetal calf serum; GusB: β-D-glucuronidase; HexA: hexosaminidase A subunit; HexB: hexosamin-
idase B subunit; Hyal1: hyaluronidase 1; IL: interleukin; MMP: matrix metalloproteinase; MV: microvesicle; NAG: β-D-N-acetyl-glucosaminidase; NOC-
18: (Z)-1-(2-(2-aminoethyl)-N-(2-ammonioethyl) amino)diazen-1-ium-1,2-diolate diethylenetriamine; OA: osteoarthritis; PCR: polymerase chain reac-
tion; RA: rheumatoid arthritis; RANTES: Regulated on Activation Normal T Cell Expressed and Secreted; RT: reverse transcriptase; SF: synovial 
fibroblast; SFl: synovial fluid; SM: synovial membrane; Spam1: sperm adhesion molecule 1; TGF-β1: tumor growth factor beta 1; TLR: Toll-like recep-
tor; TNF: tumor necrosis factor.Arthritis Research & Therapy    Vol 11 No 3    Pásztói et al.
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Introduction
Rheumatoid arthritis (RA) is a chronic, progressive systemic
autoimmune disease that affects approximately 1% of the
adult population. Proinflammatory cytokines and chemokines
are considered to be the key regulators, and certain proteases
to be the major effector molecules, in the pathomechanism of
the disease.
There has been a recent increasing awareness of the signifi-
cance of post-translational protein modifications in health and
disease. In rheumatology this is best exemplified by the signif-
icance of citrullination [1-3]. Even though glycosylation is the
most frequent post-translational modification, its role is still
poorly understood. Enzymes that collaborate to determine the
final structures of glycans are glycosyl transferases and gly-
cosidases. The significance of glycosidases has been recently
suggested by studies in which glycosidase activity resulted in
abrogation of arthritogenicity of IgG [4]. The current study
focuses on glycosidases expressed locally, within the joints.
Earlier we found very low enzyme activities of α-D-mannosi-
dase and β-D-galactosidase in serum and synovial fluid (SFl) of
patients with RA and osteoarthritis (OA). On the contrary, SFl
exoglycosidases (β-D-N-acetyl-glucosaminidase (NAG) and β-
D-glucuronidase (GusB) were characterized by significantly
elevated enzyme activities in patients with RA as compared
with OA [5]. The NAG and GusB enzymes alone or in combi-
nation with matrix metalloproteinases (MMPs) were efficient in
degrading hyaline cartilage directly [5]. The measured NAG
activity is characteristic for hexosaminidase, the enzyme
responsible for the hydrolysis of terminal nonreducing N-
acetyl-D-hexosamine.
Until recently, β-D-glucuronidase activity was attributed solely
to the lysosomal GusB enzyme. The anti-ageing klotho protein,
however, was also shown to have β-D-glucuronidase activity
[6]. Until now no study had investigated the expression of the
klotho gene in synovial fibroblasts (SFs) and synovial mem-
branes (SMs), and neither were any data available on the
expression of the hyaluronidase 1 (Hyal1) and sperm adhesion
molecule 1 (Spam1) hyaluronidase genes in the joints.
We also extended this work to the glycosidase-like Hc-gp 39
that we discovered earlier as one of the most abundant pro-
teins synthesized by SFs [7]. Hc-gp 39 is classified as a mem-
ber of the chitinase-like family 18 of proteins because of its
amino acid sequence, although no glycohydrolase activity of
this molecule has so far been demonstrated [8].
Cell-derived membrane-bound microvesicles (MVs) have also
been shown to play an important role in mediating cell – cell
communication and in the pathogenesis of several autoim-
mune diseases [9-13]. Lymphocyte-derived microvesicles
activate SFs in a dose-dependent manner to release MMPs,
proinflammatory cytokines and chemokines [13].
There is increasing evidence that SFs are key players in the
pathogenesis of RA by invading and eroding hyaline cartilage.
SFs, activated locally, produce a variety of cytokines, chemok-
ines and matrix-degrading enzymes [14].
In the present work we investigated the effect of paramount
cytokines including TNFα IL-1β, IL-17, tumor growth factor
beta 1 (TGF-β1) and we also studied MVs as potential sources
of glycosidases.
The current study describes for the first time the glycosidase
expression profile of SFs in RA and OA, and demonstrates that
glycosidases are under negative regulation in SFs.
Materials and methods
Patients
SFl samples were obtained from the knee joints of 31 patients
(six males, 25 females) with RA and of 16 patients (four males,
12 females) with OA treated in the Hospital of Hospitaller
B r o t h e r s  o f  S t  J o h n  o f  G o d ,  B u d a p e s t ,  H u n g a r y .  A l l  t h e
patients suffered from exudative synovitis.
SMs were obtained at joint replacement surgery (in the Hospi-
tal of Hospitaller Brothers of St John of God, Budapest and
the Department of Orthopedics, University Medical School of
Szeged, Hungary) from 10 RA patients (one male, nine
females; mean ± standard error mean (range) age, 61.5 ±
10.3 (25 to 79) years) and from 17 OA patients (seven males,
10 females; age, 64.53 ± 7.32 (39 to 79) years). All RA and
OA patients met the American College of Rheumatology crite-
ria for RA [15] and for OA [16], respectively.
RA patients were characterized by an erythrocyte sedimenta-
tion rate (mean ± standard error mean) of 28.60 ± 18.04 mm/
hour, as opposed to 19.00 ± 9.88 mm/hour for patients with
OA. The mean C-reactive protein level of RA patients was
22.16 ± 18.85 mg/l, but the C-reactive protein values of OA
patients were not determined. The white blood cell count of
patients with RA was 8,020 ± 1,360/μl, as compared with
7,019 ± 1,320/μl for patients with OA. The mean ± standard
error mean (range) disease duration from diagnosis of RA
patients was 10.4 ± 8.4 (0 to 35) years, as compared with 3.5
± 2.25 (1 to 10) years for OA patients. Medication of RA
patients included per os methotrexate, methylprednisolone
and sulphasalazine.
The study was approved by the Human Investigation Review
Board of the University of Szeged and all patients signed an
informed consent form.
Isolation and culture of synovial fibroblasts
SFs were obtained by enzymatic digestion as described by
Neidhart and colleagues [17]. Cells were grown in DMEM
(Sigma-Aldrich Corp, St. Louis, MO, USA) with 10% FCS
(GibcoBRL, Frederick, MD, USA). SFs were cultured for six toAvailable online http://arthritis-research.com/content/11/3/R68
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eight passages. The cell viability was higher than 95% in all
experiments. We found that the repeated passages ensured
the purity of fibroblast cell populations without contaminating
macrophages, as demonstrated by the lack of staining for
CD68 (anti-human CD68-FITC; eBioScience Inc, San Diego,
CA, USA). To rule out the possibility that SFs might have
changed their native expression profile, we tested baseline gly-
cosidase expression at every second passage, and did not
find significant alterations from the P1 to P9 passages either
in OA or RA SFs (see Additional data file 1). Gene expression
pattern of RA samples may also vary depending on the dis-
ease stage. We did not, however, test synovial tissue samples
from patients with early-stage RA in the present study.
Quantitative RT-PCR
Total RNA was extracted from SFs and SMs using the RNe-
asy® Mini Kit (Qiagen USA, Valencia, CA, USA). Relative
quantification of hexosaminidase A subunit (HexA), hexosami-
nidase B subunit (HexB), GusB, Hyal1, Hc-gp 39, klotho,
Spam1, MMP1 and MMP3 mRNAs (referred to mRNA of
hypoxanthine phosphoribosyl transferase) was performed with
TaqMan quantitative-PCR assays (Hs00166843_m1,
Hs00166864_m1, Hs99999908_m1, Hs00537920_g1,
Hs00609691_m1, Hs00183100_m1, Hs01095939_m1,
Hs00899658:m1 and Hs00233962_m1 referred to
Hs99999909_m1, respectively) on an ABI PRISM 7000
Sequence Detector (Applied Biosystems, Foster City, CA,
USA) using standard protocols [18].
Enzyme assays
SMs were homogenized in a Heidolph Diax-type homogenizer
on ice in buffer containing 0.2 M phenylmethanesulphonylfluo-
ride, 1 mg/ml PepstatinA, 0.2 M IodoAcetamid, 0.2 M ethylen-
ediamine tetraacetic acid (all purchased from Sigma-Aldrich).
SFs were lysed with five freeze – thaw cycles. Enzyme activi-
ties were normalized to protein content (50 μg protein was
used from all samples) measured by a standard Bradford pro-
tein assay. Enzyme activities were measured as described pre-
viously [5] and were expressed as units, determined using
enzymes with known activities: GUS (EC 3.2.1.31) and NAG
(EC 3.2.1.52) (all from Sigma-Aldrich).
Effect of cytokines on expression and secretion of 
glycosidases by synovial fibroblasts
SFs were cultured in the presence of human TNFα (BD Bio-
sciences Pharmingen, San Jose, CA, USA), IL-1β and TGF-β1
(both from ImmunoTools, Friesoythe, Germany) in 0, 1, 10 and
50 ng/ml concentrations, and of IL-17 (ImmunoTools) in 0, 1,
10 and 100 ng/ml concentrations for 24 hours. The nitric oxide
donor (Z)-1-(2-(2-aminoethyl)-N-(2-ammonioethyl) amino)dia-
zen-1-ium-1,2-diolate diethylenetriamine (NOC-18) (Molecu-
lar Probes, Inc., Eugene, OR, USA) was used in 100 and
1,000 μM concentrations. For enzyme release assays, 5 × 104
cells were cultured in 96-well plates in phenol-red-free-RPMI
without FCS in the presence of human TGF-β1 for 24 hours.
The enzyme activity of both the supernatants and the cell
lysates was determined as described above.
Enzyme histochemistry
SFs were plated onto chamber slides (Nunc Inc., Naperville,
IL, USA) and were cultured for 24 hours. Cells were incubated
with either 50 μM ImaGene Green C12FDGlcU β-D-glucuroni-
dase or ELF® 97 N-acetylglucosaminide substrates (both from
Molecular Probes). The slides were analyzed in a Bio-Rad
MRC 1024 confocal laser scanning microscope equipped
with a krypton/argon mixed gas laser as the light source (Bio-
Rad, Richmond, CA, USA).
Flow cytometric analysis of synovial fibroblast-derived 
microvesicles
The SFs were plated at 3 × 106 cells/75 cm2 flasks in serum-
free DMEM. After 24 hours the cell culture supernatants were
collected and the spontaneously released MVs were tested
immediately. First the supernatant was centrifuged at 500 × g
for 10 minutes to remove cells, and was then incubated either
with 50 μM ImaGene Green C12FDGlcU (the fluorogenic
lipophilic substrate of β-D-glucuronidase) or ELF®  97  N-
acetylglucosaminide substrate (both from Molecular Probes)
for 30 minutes. To verify the specificity of the reaction, D-glu-
caric acid-1,4-lactone, a β-D-glucuronidase inhibitor, was used
(Molecular Probes). The number of stained MVs was deter-
mined by measuring the events for 30 seconds by a FACSCal-
ibur (Beckton Dickinson & Co., San Jose, CA, USA) flow
cytometer.
Electron microscopy of synovial fibroblast-derived 
microvesicles
SF 24-hour supernatants were centrifuged at 500 × g for 10
minutes, and were submitted to ultracentrifugation at 100,000
× g for 30 minutes. The pellet was fixed with 2% paraformal-
dehyde/2% glutharaldehyde for 2 hours, postfixed in 1%
OsO4 for 30 minutes. The MVs were dehydrated in graded
ethanol, block-stained with 2% uranyl acetate in 70% ethanol
for 1 hour, and embedded in Taab 812 (Emmer Green, Read-
ing, UK). Ultrathin sections were examined in a Hitachi 7100
transmission electron microscope (Hitachi, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using STATISTICA 7.1
(StatSoft Inc. Tulsa, OK, USA).
The Mann – Whitney rank sum test was performed for nonre-
lated samples and the paired t test was used for cytokine-
treated samples (after a normality test was passed).
Results
Gene expression analysis
First, we analyzed the gene expression of glycosidases includ-
ing HexA, HexB, GusB, Hyal1, klotho and Hc-gp39 by quanti-Arthritis Research & Therapy    Vol 11 No 3    Pásztói et al.
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tative PCR. Gene expressions were characterized in SFs and
in SMs from RA patients and OA patients.
Gene expression of Hc-gp 39 was orders of magnitude higher
than that of any of the other tested genes (Figure 1). We have
found about 10-fold higher expression of Hc-gp 39 in SFs as
compared with SM samples.
HexA and HexB genes were characterized by the second
strongest gene expression in all samples (Figure 1). The
expression of HexA gene was approximately the same both in
SFs and in SMs. In contrast, we observed a significantly higher
expression of HexB gene in RA and OA SFs as compared with
the SMs. The expression of HexA gene has a tendency to be
higher than that of HexB in SFs of RA fibroblasts. In SM sam-
ples, however, the dominance of HexA gene expression over
HexB was highly significant.
The expression of GusB, Hyal1 and klotho showed a decreas-
ing sequence of order, as shown in Figure 2. We observed sig-
nificantly lower expression of these three genes in RA and OA
SFs as compared with that in the RA and OA SMs. In OA SMs
we found significantly higher Hyal1 expression as compared
with the RA SMs. The expression of Spam1 gene was unde-
tectable in any of the samples.
Enzyme assays
Enzyme activities were measured in SFs, SMs and SFls using
chromogenic substrates of NAG, β-D-N-acetyl-galactosamini-
dase and β-D-glucuronidase. The data are summarized in Fig-
ure 3.
Activities of NAG, β-D-N-acetyl-galactosaminidase and GusB
in RA SFls were significantly higher than in OA SFls. The activ-
ities of these enzymes in the SFls, however, were markedly
lower, quite uniformly, than those detected in the homoge-
nates of either the SMs or the SFs (Figure 3a to 3c). The activ-
ity of NAG in RA SFs was significantly higher than in RA SMs.
In contrast, the activity of GusB in SFs was lower than in SMs.
There was no significant difference in the GusB activities
associated with the SM and SF of OA and RA patients (Figure
3a to 3c).
Detection of GusB and NAG in synovial fibroblasts using 
lipophilic fluorogenic substrates
RA and OA SF monolayers were stained for GusB and NAG
using fluorogenic substrates. Both enzymes are localized to
the lysosomes. The intensity of GusB substrate fluorescence
was stronger in OA fibroblasts as compared with those iso-
lated from patients with RA (Figure 4). The NAG substrate flu-
orescence intensity was much higher than that of the β-D-
glucuronidase. The NAG staining was more intense in RA
fibroblasts as compared with those isolated from OA patients
(Figure 4).
Figure 1
Hc-gp 39, HexA and HexB gene expression in arthritis patients' syno- vial membrane and fibroblast samples Hc-gp 39, HexA and HexB gene expression in arthritis patients' syno-
vial membrane and fibroblast samples. Rheumatoid arthritis (RA) and 
osteoarthritis (OA) synovial fibroblasts (SFs) have significantly higher 
Hc-gp 39 gene expression as compared with RA and OA synovial 
membranes (SMs) (Mann – Whitney rank sum test). Hexosaminidase A 
subunit (HexA) gene expression was approximately the same in SFs 
and in SM tissue samples. Hexosaminidase B subunit (HexB) gene was 
characterized by significantly higher gene expression in RA and OA 
SFs as compared with RA and OA SM tissue samples (Mann – Whit-
ney rank sum test). Gex, gene expression; HGPRT, hypoxanthine phos-
phoribosyl transferase. *P < 0.05, **P < 0.01, ***P < 0.001.Available online http://arthritis-research.com/content/11/3/R68
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Figure 2
GusB, Hyal1 and klotho gene expression in arthritis patients' synovial  membrane and fibroblast samples GusB, Hyal1 and klotho gene expression in arthritis patients' synovial 
membrane and fibroblast samples. Gene expression for β-D-glucuroni-
dase (GusB), hyaluronidase 1 (Hyal1), and klotho genes was lower in 
rheumatoid arthritis (RA) and osteoarthritis (OA) synovial fibroblasts 
(SFs) than in RA and OA synovial membrane (SM) tissue samples 
(Mann-Whitney rank sum test). The Hyal1 gene expression was signifi-
cantly higher in OA SM as compared with RA SM (Mann – Whitney 
rank sum test). The sperm adhesion molecule 1 gene expression was 
undetectable. Gex, gene expression; HGPRT, hypoxanthine phosphori-
bosyl transferase. *P < 0.05; **P < 0.01; ***P < 0.001.
Effect of cytokines and nitric oxide on expression and 
secretion of glycosidases by synovial fibroblasts
We tested the effect of various cytokines and nitric oxide on
the gene expression of glycosidases. Relative gene expression
(referred to hypoxanthine phosphoribosyl transferase) was
determined by quantitative PCR. The relative gene expression
in the unstimulated cells for each gene was defined as 100%.
As shown in Figures 5a and 6a, TGF-β1 has significantly down-
regulated the expression of HexA and HexB genes, as well as
of GusB and Hc-gp 39. The suppression of gene expression
was more pronounced in RA than OA samples (Figures 5a and
6a), and the strongest dose-dependent downregulation was
observed in the case of Hc-gp 39 gene. TNFα downregulated
the expression of Hc-gp-39, HexB and GusB in RA (Figure
5b), and the expression of HexA gene in OA (Figure 6b). IL-1β
significantly decreased the expression of HexA, HexB and
GusB in RA (Figure 5c), while it had no effect on gene expres-
sion in OA (Figure 6c). The next cytokine tested was IL-17. As
shown in Figures 5d and 6d, stimulation of cells by IL-17 in RA
decreased the gene expression of both HexB and GusB,
whereas in OA it did not have an effect. Finally, we were inter-
ested in whether gene expression of the glycosidases was
influenced by nitric oxide. In the presence of NOC-18 there
was no change in the gene expression, except for Hc-gp 39
being downregulated in OA (Figures 5e and 6e). The expres-
sion of Hyal1 was significantly downregulated by TGF-β1 (50
ng/ml) and by IL-17 (10 ng/ml) in patients with RA. The gene
expression of Hyal1 was very low, however, in all experiments
(data not shown).
As a positive control for our assays, we also tested the expres-
sion of MMP1 and MMP3 upon stimulation by various
cytokines. In all RA SFs, the cytokine-induced upregulation of
gene expression of MMP3 was higher than fourfold. NOC-18
did not, however, induce changes in the MMP expression
(data not shown).
Since the influence of cytokines on gene expression was minor
with the exception of TGF-β1, we measured whether TGF-β1
treatment had an effect on NAG or GusB activities in both SF
lysates and in the SF supernatants. We found that most NAG
activity was detected inside the cells (Figure 7a) and showed
no significant changes under the effect of TGFβ1 either in the
cell lysates or in the supernatant (Figures 7a, b). In contrast,
minimal GusB activity was found to be associated with SFs
and most GusB activity was found in the 24-hour supernatant
of the cells (Figure 7c, d).
Although we did not detect any change in GusB activity in SF
lysates, 50 ng/ml TGF-β1 treatment resulted in a significant
decrease of secreted enzyme activity in the supernatant (Fig-
ure 7d).Arthritis Research & Therapy    Vol 11 No 3    Pásztói et al.
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Figure 4
Enzyme-histochemical detection of glycosidases in synovial fibroblast  cells Enzyme-histochemical detection of glycosidases in synovial fibroblast 
cells. Enzyme-histochemical staining of rheumatoid arthritis (RA) and 
osteoarthritis (OA) synovial fibroblast monolayers for β-D-glucuronidase 
(GusB) and β-D-N-acetyl-glucosaminidase (NAG) using fluorogenic 
substrates. Nuclear areas show no fluorescent staining.
Figure 3
Enzyme activities of synovial membrane, synovial fibroblast and synovial  fluid samples from arthritis patients Enzyme activities of synovial membrane, synovial fibroblast and synovial 
fluid samples from arthritis patients. To determine enzyme activity, the 
following chromogenic substrates were used: (a) β-D-N-acetyl-glu-
cosaminidase, (b) β-D-N-acetyl-galactosaminidase and (c) β-D-glucuro-
nidase. Optical densities were measured at 405 nm. Rheumatoid 
arthritis (RA) synovial fluid (SFl) showed significantly higher enzyme 
activities for all tested enzymes as compared with osteoarthritis (OA) 
SFl. Synovial membrane (SM) and synovial fibroblast (SF) homoge-
nates were characterized by significantly higher enzyme activities as 
compared with SFl samples. SFs showed significantly higher β-D-N-
acetyl-glucosaminidase and lower or approximately the same β-D-N-
acetyl-galactosaminidase and β-D-glucuronidase enzyme activity as 
compared with SM samples. *P < 0.05; **P < 0.01; ***P < 0.001.
Detection of synovial fibroblast-derived microvesicles 
and microvesicle-associated GusB activity
To determine whether predominant glycosidases of SFs were
also present in MVs, we tested the GusB and NAG activity
associated with MVs in SF supernatants, SFl and serum sam-
ples of RA and OA patients using a lipophilic fluorogenic sub-
strate. While we could not detect GusB activity associated
with SFl-derived and serum-derived MVs, GusB activity was
found to be associated with MVs in the supernatants of SFs of
both RA and OA patients (Figure 8). The OA SF-derived MVs
showed stronger GusB activity as compared with SF-derived
MVs from RA patients. We could not detect NAG activity in
synovial fibroblast-derived MVs using the fluorogenic NAG
substrate.
Discussion
While numerous studies have characterized the role of fibrob-
last-derived proteases in cartilage destruction [19-23], during
the past decades surprisingly little attention has been paid to
the activity of glycosidases in rheumatology. The few studies
from the 1970s that reported elevated levels of glycosidases
in joint diseases [24-26] were hardly followed by reports on
glycosidases until recently. We earlier demonstrated the ability
of exoglycosidases to degrade hyaline cartilage [5]. Popko
and colleagues [27-31] and Shikhman and colleagues [32]
reported high hexosaminidase activity in the joints of patients
with rheumatologic diseases, and Li and colleagues haveAvailable online http://arthritis-research.com/content/11/3/R68
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Figure 5
Gene expression of synovial fibroblast samples from rheumatoid arthritis patients after cytokine and NOC-18 treatment Gene expression of synovial fibroblast samples from rheumatoid arthritis patients after cytokine and NOC-18 treatment. Synovial fibroblasts (SFs) 
from patients with rheumatoid arthritis (RA) were cultured in the presence or absence of various cytokines or the nitric oxide donor (Z)-1-(2-(2-ami-
noethyl)-N-(2-ammonioethyl) amino)diazen-1-ium-1,2-diolate diethylenetriamine (NOC-18) for 24 hours. Relative gene expression (referred to hypox-
anthine phosphoribosyl transferase) was determined by realtime PCR. The relative gene expression in the unstimulated cells for each gene is defined 
as 100%. (a) Tumor growth factor beta 1 (TGF-β1) stimulation (n = 4). (b) TNFα stimulation (n = 6). (c) IL-1β stimulation (n = 4). (d) IL-17 stimula-
tion (n = 4). (e) NOC-18 stimulation (n = 3). Data shown as mean ± standard error mean. *P < 0.05, **P < 0.01, ***P < 0.0015 (paired t test). 
GusB, β-D-glucuronidase; HexA, hexosaminidase A subunit; HexB, hexosaminidase B subunit.Arthritis Research & Therapy    Vol 11 No 3    Pásztói et al.
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recently shown an increased heparanase activity in RA SFl and
tissue [33]. The synovial glycosidase gene expression pattern
has not yet been described, however, and it also remained
unclear whether the gene expression of glycosidases in SFs
was regulated by inflammatory cytokines.
We found a robust gene expression of the glycosidase-like
Hc-gp 39 in the SMs, and in particular in SFs, of both RA and
OA patients. The strikingly elevated Hc-gp 39 expression in
SFs as compared with the SMs may be explained either by
inhibition of its expression within the synovium or by upregula-
tion of it by factors during in vitro growth of fibroblasts.
Figure 6
Gene expression of synovial fibroblast samples from osteoarthritis patients after cytokine and NOC-18 treatment Gene expression of synovial fibroblast samples from osteoarthritis patients after cytokine and NOC-18 treatment. Synovial fibroblasts (SFs) from 
patients with osteoarthritis (OA) were cultured in the presence or absence of various cytokines or the nitric oxide donor (Z)-1-(2-(2-aminoethyl)-N-(2-
ammonioethyl) amino)diazen-1-ium-1,2-diolate diethylenetriamine (NOC-18) for 24 hours. Relative gene expression (referred to hypoxanthine phos-
phoribosyl transferase) was determined by realtime PCR. The relative gene expression in the unstimulated cells for each gene is defined as 100%. 
(a) Tumor growth factor beta 1 (TGF-β1) stimulation (n = 6). (b) TNFα stimulation (n = 6). (c) IL-1β stimulation (n = 3). (d) IL-17 stimulation (n = 3). 
(e) NOC-18 stimulation (n = 3). Data shown as mean ± standard error mean. *P < 0.05, **P < 0.01, ***P < 0.0015 (paired t test). GusB, β-D-glu-
curonidase; HexA, hexosaminidase A subunit; HexB, hexosaminidase B subunit.Available online http://arthritis-research.com/content/11/3/R68
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According to our data, hexosaminidase is the glycosidase with
the highest expression and activity in the joints. This is in
accordance with the findings of previous studies [29].
In the present study we show that SFs appear to be major
sources of this enzyme in the SMs as they are characterized
by strong expression of both HexA and HexB genes. Hex-
osaminidase A is composed of both alpha and beta chains,
whereas hexosaminidase B is a homodimer of beta chains.
The rare hexosaminidase S izoenzyme is composed from HexA
– HexA gene products [34,35]. In this work we found a signif-
icantly higher expression of HexA compared with HexB in SFs
and SM samples. This raises the intriguing possibility of
intraarticular expression of the rare hexosaminidase S, respon-
sible for degradation of sulfated glycosaminoglycans [36].
We hypothesize that even though SFs show relatively low
expression of GusB, they might accumulate significant
amounts of this lysosomal enzyme – some of which might be
released by cell-derived MVs. This concept is supported by
the GusB activity detected in cell lysates that was comparable
with that detected in SM homogenates, and also by its asso-
ciation with cell-derived MVs.
The association of GusB activity with SF-derived MVs sheds
light on a previously unrecognized localization of this enzyme.
Innate immunity plays a key role in the initiation of an immune
response. Its germline encoded receptors such as Toll-like
receptors (TLRs) detect danger signals. Functional TLR2 was
reported in SFs of patients who had RA [37,38]. RA SFs, acti-
vated via TLR2, were suggested to contribute to arthritis
development by secretion of chemokines. While exogenous
TLR ligands have been investigated extensively, only few
endogenous TLR ligands have so far been identified. These
ligands include carbohydrate degradation products of the
extracellular matrix (tetrasaccharides and hexasaccharides of
hyaluronate and heparan sulphate) [39-41]. Interestingly, all
known carbohydrate TLR ligands fall into the category of oli-
gosaccharides generated by endoglycosidases, enzymes that
Figure 7
Enzyme activities of synovial fibroblast samples of rheumatoid arthritis and osteoarthritis patients after TGF-β1 treatment Enzyme activities of synovial fibroblast samples of rheumatoid arthritis and osteoarthritis patients after TGF-β1 treatment. Synovial fibroblasts (SFs) 
from patients with rheumatoid arthritis (RA) (n = 6) or osteoarthritis (OA) (n = 6) were cultured in the presence or absence of tumor growth factor 
beta 1 (TGF) for 24 hours. β-D-N-acetyl-glucosaminidase (NAG) and β-D-glucuronidase (GusB) activities were determined in cell lysates and the 
corresponding supernatants (S/N): (a) NAG in cell lysate, (b) NAG in supernatant, (c) GusB in cell lysate and (d) GusB in supernatant. Most NAG 
activity was found inside the SFs, while GusB was predominantly secreted into the supernatant. Data shown as mean ± standard error mean. P < 
0.01 ***.Arthritis Research & Therapy    Vol 11 No 3    Pásztói et al.
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cleave polysaccharide chains between nonterminal residues.
The endoglycosidases that we have tested in the present
study (Hyal1 and Spam1) showed minimal activity within the
joints. Based on our results, therefore, it seems very likely that
the carbohydrate degradation product ligands for TLRs are
generated by exogenous (for example, microbial) endoglycosi-
dases rather then SM-derived or SF-derived enzymes.
In line with earlier data, we found that hexosaminidase was the
dominant exoglycosidase in the joints. Constitutive generation
of cleavage products such as glucosamine by hexosaminidase
may be part of the normal extracellular matrix/glycosaminogly-
can turnover. Glucosamine has been recently shown to glo-
bally protect chondrocytes from the arthritogenic effects of IL-
1β (by blocking the response in ~73% of IL-1β-stimulated
genes) [42]. Glucosamine might therefore act primarily as an
endogenous anti-inflammatory molecule within the joints.
Under physiological conditions, hexosaminidase cleavage
products may thus play a protective role and maintain tissue
homeostasis, while this homeostatic balance may be shifted
during microbial infections. In acute inflammation, frustrated
phagocytosis and elevated intracellular free calcium level-
induced secretion of lysosomal resident enzymes may result in
significant release of further exoglycosidases by infiltrating
cells (for example, monocytes and neutrophil granulocytes)
[43] that might act in concert with SF-derived hexosaminidase.
Upon the alternating action of certain exoglycosidases (hex-
osaminidase and glucuronidase), cartilage matrix degradation
may dominate and lead to the release of glycosaminoglycans
from the extracellular matrix.
One of the most striking findings of our study was that the reg-
ulation of gene expression of glycosidases and proteases by
cytokines seems to be discordant. In sharp contrast to MMPs
and other proteases, such as certain cathepsins – which have
been reported to be highly inducible by proinflammatory
Figure 8
Detection of synovial fibroblast-derived microvesicles and microvesicle-associated GusB activity Detection of synovial fibroblast-derived microvesicles and microvesicle-associated GusB activity. (a) Synovial fibroblast (SF)-derived microvesicles 
(MVs) were isolated from serum-free 24-hour fibroblast supernatants by centrifugation and subsequent ultracentrifugation at 100,000 × g. Electron 
micrographs show different MVs varying in size and morphology. The dominant microvesicle type appears to be ectosome (diameter between 100 
and 800 nm). (b) Flow cytometric scatter plots of 24-hour supernatants of SFs with cell-derived microvesicles. SSC-H (side scatter), FSC-H (for-
ward scatter). (c), (d) Histogram plots show that the majority of rheumatoid arthritis (RA) and osteoarthritis (OA) SF-derived microvesicles are β-D-
glucuronidase (GusB)-positive when stained with a lipophilic fluorogenic substrate. OA synovial fibroblast-derived MVs are characterized by 
stronger mean fluorescence intensity values than those derived from RA SFs. FL1-H (histogram of the green fluorescence).Available online http://arthritis-research.com/content/11/3/R68
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cytokines [44-47] – we found that glycosidases were moder-
ately downregulated by proinflammatory cytokines IL-1β, IL-17
and TNFα. The most pronounced cytokine effect was seen in
the case of TGF-β1, which profoundly downregulated glycosi-
dase expression in both RA and OA fibroblasts.
Transforming growth factor beta is found abundantly in the SM
[48], and constitutive upregulation of the transforming growth
factor beta pathway has been shown in RA SFs [49]. Trans-
forming growth factor beta exerts both anti-inflammatory and
proinflammatory actions, as exemplified by its ability to down-
regulate RANTES expression and by stimulating the synthesis
of MMP-1 and IL-1 [50].
We hypothesize that the relatively stable expression and tight
regulation control of synovial glycosidases are critical factors
in the joints. Numerous cytokines exert complex regulatory
mechanisms in RA. Our observation that glycosidases appear
to be under negative control and are downregulated rather
than stimulated by inflammatory cytokines may suggest that an
enhanced expression of these enzymes could lead to severe
and unforeseeable consequences. The extracellular matrix has
been reported to serve as a repository of transforming growth
factor beta and other growth factors of which the release is
regulated via degradation of proteoglycans [51]. The long list
of glycosaminoglycan binding proteins includes growth fac-
tors (like fibroblast growth factors, vascular endothelial growth
factor, insulin-like growth factor-binding proteins), morpho-
gens, enzymes, numerous cytokines and chemokines, inter-
leukins, and so forth [52]. It can be hypothesized that a
stringent control of the gene expression of glycosidases may
prevent the synchronized release of the plethora of tissue-
bound proteins.
Until recently, GusB has been regarded as a housekeeping
gene in humans due to the absence of TATA box and high
G+C contents within its putative promoter sequence [53].
Downregulation of GusB expression was demonstrated
recently by the calcium ionophore A23187, the calcium
ATPase inhibitor thapsigargin as well as by the calcium chan-
nel blocker verapamil in the human hepatoma cell line HepG2
[54]. The present study provides the first evidence that gly-
cosidase gene expression (including the one of GusB) is reg-
ulated by human cytokines.
Conclusions
Our data drive attention to the dominant negative regulation of
a functional group of genes – glycosidases – by paramount
cytokines in SFs that differs remarkably from regulation of pro-
teases. The fact that we did not find significant differences
between patients with RA and OA with respect to their gly-
cosidase gene expression suggests a similar role and regula-
tion for exoglycosidases in the two diseases. This hypothesis
does not contradict these enzymes contributing significantly to
cartilage degradation in both joint diseases if acting in concert
with MMPs to deplete cartilage in glycosaminoglycans. Our
data suggest that the earlier reported elevated glycosidase
activities in RA joints were probably not due to enhanced gene
expression of resident SFs, but rather resulted from enzyme
release by cells (including infiltrating inflammatory cells) within
the joints.
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